Market Overview

Quanterix Announces Termination of License Agreement with bioMérieux


Secures and Consolidates Unrestricted Rights for Simoa Technology in
Diagnostics Market

(NASDAQ:QTRX), a company digitizing biomarker analysis
with the goal of advancing the science of precision health, today
announced the consolidation of its licensing position and
reestablishment of control of its intellectual property in the in
diagnostics (IVD) field. The termination of the license
agreement by bioMérieux reinstates to Quanterix all rights and
privileges associated with its Simoa technology.

"While we have benefited from our six-year strategic relationship with
bioMérieux for commercializing Simoa into IVD markets, this development
unlocks our long-term value creation opportunity in the estimated $30B
IVD market," said Kevin Hrusovsky, Chief Executive Officer, President
and Chairman of Quanterix. "Over the last several years we have built a
formidable business and momentum in research use only (RUO) markets
validating our technology's disruptive potential in neurology, oncology,
infectious disease, inflammation and immune disorders, while
bioMérieux's investments have been integral in advancing the Simoa
technology in IVD. Quanterix now has strategic optionality to capitalize
on a broad range of IVD markets and opportunities beyond bioMérieux's
primary focus of infectious disease and immunology. We look forward to
continuing our close collaboration with bioMérieux as it remains one of
our strongest customers for Simoa."

About Quanterix
Quanterix is a company that's digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company's digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease. Quanterix' technology is designed to enable much earlier
disease detection, better prognoses and enhanced treatment methods to
improve the quality of life and longevity of the population for
generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology,
neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Lexington, Massachusetts. For
additional Information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release are based on Quanterix' expectations and assumptions as of
the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may cause Quanterix'
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed
in Quanterix' filings with the U.S. Securities and Exchange Commission,
including the "Risk Factors" sections contained therein. Except as
required by law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change in
expectations, even as new information becomes available.

View Comments and Join the Discussion!